In conclusion, we proposed that the miR-622/NUAK1 axis controls tumour cell migration and invasion of breast cancer cell lines and, relevantly, our results support the notion that miR-622 and NUAK1 kinase could have clinical utility both as predictive biomarkers and as therapeutic targets in breast cancer patients. This evidence concerns the gene NUAK1 and neoplasm.